Neovii

Neovii is an independent global biopharmaceutical company with a mission to develop and bring to market novel life-transforming therapies that are patient-focused, aiming to improve outcomes in transplant medicine, hemato-oncology, and immune diseases. Their leading product, Grafalon®, has been used to treat patients for over 30 years and is available in more than 50 countries worldwide. It is approved for use in immunosuppressive therapy to prevent graft-versus-host disease in stem cell transplantation, prevent and treat rejection in solid organ transplantation, and for aplastic anemia.